
FDA issues US-wide recall of Mylan’s EpiPen
pharmafile | April 3, 2017 | News story | Medical Communications, Sales and Marketing | FDA, Mylan, epipen
After recent reports of around 80,000 defective EpiPen’s across Australia, New Zealand, Japan, Norway, Denmark, Finland and Ireland, the FDA has called for a voluntary nationwide recall of Mylan’s auto-injector in the US after news that products in that region are also failing to activate properly.
“The expanded voluntary recall is being initiated in the US and also will extend to additional markets in Europe, Asia, North and South America,” Mylan said.
The recall concerns a small number of devices across 13 lots, which have been manufactured with defective parts which prevent them for working correctly. All those with non-working products will be offered a replacement, but must contact Mylan directly. The FDA is also requesting that anyone affected reports it to its Medwatch website. Generic versions of the product are exempt from the recall.
All EpiPen models are manufactured at a single plant in St Louis, Missouri, so it is as yet unclear what caused the defective issue in the first place, or why this new wave of ineffective models was not included in the original recall in March.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …





